Investigational New Drugs

, Volume 29, Issue 6, pp 1432–1440 | Cite as

Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium

  • Deborah A. Bradley
  • Stephanie Daignault
  • Charles J. Ryan
  • Robert S. DiPaola
  • David C. Smith
  • Eric Small
  • Mitchell E. Gross
  • Mark N. Stein
  • Alice Chen
  • Maha HussainEmail author


Background Integrins are involved in prostate cancer metastasis by regulating cell adhesion, migration, invasion, motility, angiogenesis and bone metabolism. We evaluated the efficacy of two dose levels of cilengitide in patients (pts) with castrate resistant prostate cancer (CRPC). Methods Chemotherapy-naïve, asymptomatic metastatic CRPC pts were randomized to cilengitide 500 mg or 2,000 mg IV twice weekly using parallel 2-stage design. The primary endpoint was rate of objective clinical progression at 6-months. Secondary endpoints included clinical and PSA response rates, safety and effects of cilengitide treatment on circulating tumor cells (CTCs) and bone remodeling markers. Results Forty-four pts were accrued to first stage (22/arm). Median number of cycles was three in both arms (500 mg arm: 1–8; 2,000 mg arm: 1–15). At 6 months, two pts (9%) on the 500 mg arm and five pts (23%) on the 2,000 mg arm had not progressed. Best objective response was stable disease (SD) in seven pts for 9.9[8.1,20.9] months. There were three grade 3 and no grade 4 toxicities. At 12 weeks, analysis of bone markers did not reveal significant trends. At progression, bone specific alkaline phosphatase and N-telopeptide increased in all pts, less so in pts on the 2,000 mg arm and in pts on both arms who obtained SD at 6 months. CTCs increased over time in both arms. Conclusion Cilengitide was well tolerated with modest clinical effect in favor of the higher dose. The unique trial design including a shift from response rate to objective progression as the endpoint, and not acting on PSA increases was feasible.


Prostate cancer Metastatic disease Integrins Angiogenesis Cilengitide Bone biomarkers 



CTEP, Prostate SPORE Grant P50 CA069568-09, Merck KGaA, PC051382, PC051375, PCF N008367, Immunicon Corporation.


  1. 1.
    EMD 121974 Cilengitide, cyclo-[Arg-Gly-Asp-DPhe-(NMeVal)]. Investigator’s BrochureGoogle Scholar
  2. 2.
    Albelda SM (1993) Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 68:4–17PubMedGoogle Scholar
  3. 3.
    Allen MV, Smith GJ, Juliano R, Maygarden SJ, Mohler JL (1998) Downregulation of the beta4 integrin subunit in prostatic carcinoma and prostatic intraepithelial neoplasia. Hum Pathol 29:311–318PubMedCrossRefGoogle Scholar
  4. 4.
    Assoian RK, Schwartz MA (2001) Coordinate signaling by integrins and receptor tyrosine kinases in the regulation of G1 phase cell-cycle progression. Curr Opin Genet Dev 11:48–53PubMedCrossRefGoogle Scholar
  5. 5.
    Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157–1164PubMedCrossRefGoogle Scholar
  6. 6.
    Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59–69PubMedCrossRefGoogle Scholar
  7. 7.
    Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G et al (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J Clin Oncol 17:3461–3467PubMedGoogle Scholar
  8. 8.
    Carducci M, Nelson JB, Saad F, Schulman CC, Dearnaley DP, Sleep DJ, Hulting SM, Isaacson JD, Allen A, Nisen P (2004) Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: phase 3 study. J Clin Oncol 22:4508Google Scholar
  9. 9.
    Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB (2003) Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21:679–689PubMedCrossRefGoogle Scholar
  10. 10.
    Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA, Sleep DJ, Isaacson JD, Nelson JB (2007) A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110:1959–1966PubMedCrossRefGoogle Scholar
  11. 11.
    Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23:4925–4935PubMedCrossRefGoogle Scholar
  12. 12.
    Cooper CR, Chay CH, Pienta KJ (2002) The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia 4:191–194PubMedCrossRefGoogle Scholar
  13. 13.
    Cooper CR, Pienta KJ (2000) Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a minireview. Prostate Cancer Prostatic Dis 3:6–12PubMedCrossRefGoogle Scholar
  14. 14.
    Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI (2007) Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13:7053–7058PubMedCrossRefGoogle Scholar
  15. 15.
    Davis TL, Cress AE, Dalkin BL, Nagle RB (2001) Unique expression pattern of the alpha6beta4 integrin and laminin-5 in human prostate carcinoma. Prostate 46:240–248PubMedCrossRefGoogle Scholar
  16. 16.
    de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302–6309PubMedCrossRefGoogle Scholar
  17. 17.
    Duong LT, Lakkakorpi P, Nakamura I, Rodan GA (2000) Integrins and signaling in osteoclast function. Matrix Biol 19:97–105PubMedCrossRefGoogle Scholar
  18. 18.
    Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Bottcher S, Wynendaele W, Drevs J, Verweij J, van Oosterom AT (2003) Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39:917–926PubMedCrossRefGoogle Scholar
  19. 19.
    Fornaro M, Manes T, Languino LR (2001) Integrins and prostate cancer metastases. Cancer Metastasis Rev 20:321–331PubMedCrossRefGoogle Scholar
  20. 20.
    Hariharan S, Gustafson D, Holden S, McConkey D, Davis D, Morrow M, Basche M, Gore L, Zang C, O’Bryant CL, Baron A, Gallemann D, Colevas D, Eckhardt SG (2007) Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol 18:1400–1407PubMedCrossRefGoogle Scholar
  21. 21.
    Holly SP, Larson MK, Parise LV (2000) Multiple roles of integrins in cell motility. Exp Cell Res 261:69–74PubMedCrossRefGoogle Scholar
  22. 22.
    Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91–100PubMedCrossRefGoogle Scholar
  23. 23.
    Hughes DE, Salter DM, Dedhar S, Simpson R (1993) Integrin expression in human bone. J Bone Miner Res 8:527–533PubMedCrossRefGoogle Scholar
  24. 24.
    Keller ET, Brown J (2004) Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 91:718–729PubMedCrossRefGoogle Scholar
  25. 25.
    Knox JD, Cress AE, Clark V, Manriquez L, Affinito KS, Dalkin BL, Nagle RB (1994) Differential expression of extracellular matrix molecules and the alpha 6-integrins in the normal and neoplastic prostate. Am J Pathol 145:167–174PubMedGoogle Scholar
  26. 26.
    Lara PN Jr, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara DR (2006) A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res 12:1556–1563PubMedCrossRefGoogle Scholar
  27. 27.
    Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, Coleman RE (2008) Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113:193–201PubMedCrossRefGoogle Scholar
  28. 28.
    MacDonald TJ, Stewart CF, Kocak M, Goldman S, Ellenbogen RG, Phillips P, Lafond D, Poussaint TY, Kieran MW, Boyett JM, Kun LE (2008) Phase I clinical trial of cilengitide in children with refractory brain tumors: pediatric brain tumor consortium study PBTC-012. J Clin Oncol 26:919–924PubMedCrossRefGoogle Scholar
  29. 29.
    Moreno J, DeBono JS, Shaffer D, Montgomery B, Miller MC, Tissing H, Doyle G, Terstappen LW, Pienta KJ, Raghavan D (2007) Multi-center study evaluating circulating tumor cells (CTCs) as a surrogate for survival in men treated for castration refractory prostate cancer (CRPC). J Clin Oncol 25: abstract 5016Google Scholar
  30. 30.
    Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW (2005) Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 65:713–718PubMedCrossRefGoogle Scholar
  31. 31.
    Murant SJ, Handley J, Stower M, Reid N, Cussenot O, Maitland NJ (1997) Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer 33:263–271PubMedCrossRefGoogle Scholar
  32. 32.
    Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K, Wittemer SM, Colevas AD, Grossman SA (2007) Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25:1651–1657PubMedCrossRefGoogle Scholar
  33. 33.
    Nagle RB, Knox JD, Wolf C, Bowden GT, Cress AE (1994) Adhesion molecules, extracellular matrix, and proteases in prostate carcinoma. J Cell Biochem Suppl 19:232–237PubMedGoogle Scholar
  34. 34.
    Nakamura I, Pilkington MF, Lakkakorpi PT, Lipfert L, Sims SM, Dixon SJ, Rodan GA, Duong LT (1999) Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone. J Cell Sci 112(Pt 22):3985–3993PubMedGoogle Scholar
  35. 35.
    Nemeth JA, Cher ML, Zhou Z, Mullins C, Bhagat S, Trikha M (2003) Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis 20:413–420PubMedCrossRefGoogle Scholar
  36. 36.
    Pidgeon GP, Tang K, Cai YL, Piasentin E, Honn KV (2003) Overexpression of platelet-type 12-lipoxygenase promotes tumor cell survival by enhancing alpha(v)beta(3) and alpha(v)beta(5) integrin expression. Cancer Res 63:4258–4267PubMedGoogle Scholar
  37. 37.
    Reardon D, Fink K, Nabors B, Cloughesy T, Plotkin S, Schiff D, Raizer J, Krueger S, Picard M, Mikkelsen T (2007) Phase IIa trial of cilengitide (EMD121974) single-agent therapy in patients (pts) with recurrent glioblastoma (GBM): EMD 121974-009. J Clin Oncol 25: abstract 2002Google Scholar
  38. 38.
    Rodan SB, Rodan GA (1997) Integrin function in osteoclasts. J Endocrinol 154(Suppl):S47–S56PubMedGoogle Scholar
  39. 39.
    Rowand JL, Martin G, Doyle GV, Miller MC, Pierce MS, Connelly MC, Rao C, Terstappen LW (2007) Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas. Cytometry A 71:105–113PubMedGoogle Scholar
  40. 40.
    Ruoslahti E, Reed JC (1994) Anchorage dependence, integrins, and apoptosis. Cell 77:477–478PubMedCrossRefGoogle Scholar
  41. 41.
    Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468PubMedGoogle Scholar
  42. 42.
    Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 26:1148–1159PubMedCrossRefGoogle Scholar
  43. 43.
    Schmelz M, Cress AE, Scott KM, Burger F, Cui H, Sallam K, McDaniel KM, Dalkin BL, Nagle RB (2002) Different phenotypes in human prostate cancer: alpha6 or alpha3 integrin in cell-extracellular adhesion sites. Neoplasia 4:243–254PubMedCrossRefGoogle Scholar
  44. 44.
    Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ (2004) Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64:9209–9216PubMedCrossRefGoogle Scholar
  45. 45.
    Simon R, Wittes RE, Ellenberg SS (1985) Randomized phase II clinical trials. Cancer Treat Rep 69:1375–1381PubMedGoogle Scholar
  46. 46.
    Slack-Davis JK, Parsons JT (2004) Emerging views of integrin signaling: implications for prostate cancer. J Cell Biochem 91:41–46PubMedCrossRefGoogle Scholar
  47. 47.
    Stewart DA, Cooper CR, Sikes RA (2004) Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer. Reprod Biol Endocrinol 2:2PubMedCrossRefGoogle Scholar
  48. 48.
    Tantivejkul K, Kalikin LM, Pienta KJ (2004) Dynamic process of prostate cancer metastasis to bone. J Cell Biochem 91:706–717PubMedCrossRefGoogle Scholar
  49. 49.
    Vogelzang N, Nelson J, Schulman C, Dearnaley D, Saad F, Sleep D, Isaacson J, Carducci M (2005) Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer. J Clin Oncol 23:4563Google Scholar
  50. 50.
    Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR (1999) Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 59:1655–1664PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Deborah A. Bradley
    • 1
  • Stephanie Daignault
    • 2
  • Charles J. Ryan
    • 3
  • Robert S. DiPaola
    • 4
  • David C. Smith
    • 2
  • Eric Small
    • 3
  • Mitchell E. Gross
    • 5
  • Mark N. Stein
    • 4
  • Alice Chen
    • 6
  • Maha Hussain
    • 2
    • 7
    Email author
  1. 1.Duke UniversityDurhamUSA
  2. 2.University of MichiganAnn ArborUSA
  3. 3.University of CaliforniaSan FranciscoUSA
  4. 4.The Cancer Institute of New JerseyNew BrunswickUSA
  5. 5.Cedars-Sinai Medical CenterLos AngelesUSA
  6. 6.NCI/CTEPBethesdaUSA
  7. 7.University of Michigan Medical CenterAnn ArborUSA

Personalised recommendations